Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors

23

description

- PowerPoint PPT Presentation

Transcript of Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors

Page 1: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 2: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 3: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 4: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 5: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 6: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 7: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 8: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 9: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 10: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 11: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 12: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 13: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 14: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 15: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 16: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 17: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 18: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 19: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 20: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 21: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 22: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 23: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors

Oral Antidiabetic Agents-Review and Updates€¦ · 16 Keywords: Antidiabetic drugs, DPP-4 inhibitors, metformin, oral hypoglycemic agents (OHA), saroglitazar, SGLT 2 17 inhibitors,

Oral Antidiabetic Agents-Review and Updates€¦ · 16 Keywords: Antidiabetic drugs, DPP-4 inhibitors, metformin, oral hypoglycemic agents (OHA), saroglitazar, SGLT 2 17 inhibitors,

Comorbidities in Cerebr

Comorbidities in Cerebr

2018 ANNUAL TREND REPORT · 2020-04-30 · FOCUS ON DIABETES As predicted in our 2016 Trend Report, GLP-1 agonist and SGLT2 inhibitors have gained more market share than DPP-IV inhibitors

2018 ANNUAL TREND REPORT · 2020-04-30 · FOCUS ON DIABETES As predicted in our 2016 Trend Report, GLP-1 agonist and SGLT2 inhibitors have gained more market share than DPP-IV inhibitors

DPP 2011 Vs. DPP 2009 and DPP 2008

DPP 2011 Vs. DPP 2009 and DPP 2008

 · Web viewThree dipeptidyl-peptidase 4 (DPP-4) inhibitors are currently available in the United States: sitagliptin, saxagliptin and linagliptin. None of the DPP-4 inhibitors are

 · Web viewThree dipeptidyl-peptidase 4 (DPP-4) inhibitors are currently available in the United States: sitagliptin, saxagliptin and linagliptin. None of the DPP-4 inhibitors are

Utah Medicaid Pharmacy and Therapeutics Committee Drug Class … ·  · 2019-10-30Introduction: Dipeptidylpeptidase-4 inhibitors (DPP-4i) are oral medications indicated for adults

Utah Medicaid Pharmacy and Therapeutics Committee Drug Class … ·  · 2019-10-30Introduction: Dipeptidylpeptidase-4 inhibitors (DPP-4i) are oral medications indicated for adults

The effects of DPP-4 inhibitors on vascular endothelial function in … · 2016. 5. 4. · The effects of DPP-4 inhibitors on vascular endothelial function in diabetes A thesis submitted

The effects of DPP-4 inhibitors on vascular endothelial function in … · 2016. 5. 4. · The effects of DPP-4 inhibitors on vascular endothelial function in diabetes A thesis submitted

Oral Anti-Diabetic Agents-Review and Updates€¦ · Keywords: Antidiabetic drugs; DPP-4 inhibitors; metformin; oral hypoglycemic agents (OHA); saroglitazar; SGLT 2 inhibitors; sulphonylureas.

Oral Anti-Diabetic Agents-Review and Updates€¦ · Keywords: Antidiabetic drugs; DPP-4 inhibitors; metformin; oral hypoglycemic agents (OHA); saroglitazar; SGLT 2 inhibitors; sulphonylureas.

PHARMACOLOGICAL MANAGEMENT OF PATIENTS WITH TYPE 2 …ijsit.com/admin/ijsit_files/PHARMACOLOGICAL MANAGEMENT OF... · 2019-03-02 · f) DPP-4 inhibitors: The DPP-4 Inhibitors is not

PHARMACOLOGICAL MANAGEMENT OF PATIENTS WITH TYPE 2 …ijsit.com/admin/ijsit_files/PHARMACOLOGICAL MANAGEMENT OF... · 2019-03-02 · f) DPP-4 inhibitors: The DPP-4 Inhibitors is not

Combining MK626, a Novel DPP-4 Inhibitor, and Low- Dose ... · strategy in type 1 diabetes cure. Dipeptidyl peptidase-4 (DPP-4) inhibitors elevate circulating levels of active incretins,

Combining MK626, a Novel DPP-4 Inhibitor, and Low- Dose ... · strategy in type 1 diabetes cure. Dipeptidyl peptidase-4 (DPP-4) inhibitors elevate circulating levels of active incretins,

2018 ANNUAL TREND REPORT...As predicted in our 2016 Trend Report, GLP-1 agonist and SGLT2 inhibitors have gained more market share than DPP-IV inhibitors due to their ability to reduce

2018 ANNUAL TREND REPORT...As predicted in our 2016 Trend Report, GLP-1 agonist and SGLT2 inhibitors have gained more market share than DPP-IV inhibitors due to their ability to reduce

Side Effects of · 2018-04-29 · Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018

Side Effects of · 2018-04-29 · Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018

Research Article Renal Protective Effect of DPP-4 ...downloads.hindawi.com/journals/jdr/2016/1423191.pdf · Research Article Renal Protective Effect of DPP-4 Inhibitors in Type 2

Research Article Renal Protective Effect of DPP-4 ...downloads.hindawi.com/journals/jdr/2016/1423191.pdf · Research Article Renal Protective Effect of DPP-4 Inhibitors in Type 2

A New Therapy of Type 2 Diabetes: DPP-4 Inhibitors

A New Therapy of Type 2 Diabetes: DPP-4 Inhibitors

DPP-4 Inhibitors: ‘GLIPTINS’ - FLAME · 2019-04-21 · MECHANISM OF ACTION u Dipeptidyl peptidase 4 (DPP-4) acts to inhibit incretins GIP and GLP-1 at the pancreatic islets u

DPP-4 Inhibitors: ‘GLIPTINS’ - FLAME · 2019-04-21 · MECHANISM OF ACTION u Dipeptidyl peptidase 4 (DPP-4) acts to inhibit incretins GIP and GLP-1 at the pancreatic islets u

Dipeptidyl peptidase 4 (DPP-4) inhibitors and ......Dipeptidyl peptidase 4 (DPP-4) inhibitors are newer anti-diabetic agents which have shown to well maintain blood glucose level over

Dipeptidyl peptidase 4 (DPP-4) inhibitors and ......Dipeptidyl peptidase 4 (DPP-4) inhibitors are newer anti-diabetic agents which have shown to well maintain blood glucose level over

Comparative Safety and Effectiveness of Type 2 …€¦ · Web viewBennett 2011 did not include sodium glucose co-transporter 2 (SGLT2) inhibitors or DPP-4 inhibitors.1 Therefore,

Comparative Safety and Effectiveness of Type 2 …€¦ · Web viewBennett 2011 did not include sodium glucose co-transporter 2 (SGLT2) inhibitors or DPP-4 inhibitors.1 Therefore,

Efficacy and safety of dipeptidyl peptidase-4 inhibitors · DPP-4 inhibitors did not induce a higher rate of hy - poglycemia (RR=1.31, 95%CI: 0.97, 1.77; p =0.075). CONCLUSIONS: DPP-4

Efficacy and safety of dipeptidyl peptidase-4 inhibitors · DPP-4 inhibitors did not induce a higher rate of hy - poglycemia (RR=1.31, 95%CI: 0.97, 1.77; p =0.075). CONCLUSIONS: DPP-4

Type 2 Diabetes Treatment: Novel Therapies GLP-1 Receptor Agonists/Analogs and DPP-4 Inhibitors

Type 2 Diabetes Treatment: Novel Therapies GLP-1 Receptor Agonists/Analogs and DPP-4 Inhibitors

Differences in the glucose-lowering efficacy of dipeptidyl ... · 1c-lowering efficacy of DPP-4 inhibitors at the end of the study. Secondary outcomes were the effect of DPP-4 inhibitors

Differences in the glucose-lowering efficacy of dipeptidyl ... · 1c-lowering efficacy of DPP-4 inhibitors at the end of the study. Secondary outcomes were the effect of DPP-4 inhibitors